Immunomedics has received a patent for a technology that could lead to the development of vaccines for cancer, the Morris Plains, NJ, company reported today. The patent is one of several the company has received for vaccine-related technology.
Immunomedics reported today that the U.S. Patent and Trademark Office has issued a patent allowance to the company for the technology, which involves the "coating" of an alpha-galactose molecule on cancer cells or microorganisms by a fusion protein. Since patients have naturally occurring antibodies to alpha-galactose, these antibodies can be activated to become therapeutic agents against cancers or infectious diseases.
Immunomedics has developed several monoclonal antibody-labeled radiopharmaceuticals for imaging applications, such as its CEA-Scan agent, but lately the company has focused on therapy products.
By AuntMinnie.com staff writers
February 2, 2000
Copyright © 2000 AuntMinnie.com
